BIOMAT Database Logo BIOMAT Database Logo

Decreased plasma endothelin-1 levels in children with sickle cell disease treated with hydroxyurea. 2005

Claudine Lapouméroulie, and Malika Benkerrou, and Marie Hélène Odièvre, and Rolande Ducrocq, and Manuel Brun, and Jacques Elion

Plasma endothelin-1 (ET-1) is elevated in patients with sickle cell disease (SCD). Hydroxyurea (HU) is the only drug with demonstrated clinical efficacy in SCD. Here we show that treatment with HU results in a decreased concentration of circulating ET-1 which is not correlated with the HU-induced increase in HbF level. Blunting of the ET-1 vasoconstrictive stimulus could contribute to the beneficial effects of HU.

UI MeSH Term Description Entries
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005319 Fetal Hemoglobin The major component of hemoglobin in the fetus. This HEMOGLOBIN has two alpha and two gamma polypeptide subunits in comparison to normal adult hemoglobin, which has two alpha and two beta polypeptide subunits. Fetal hemoglobin concentrations can be elevated (usually above 0.5%) in children and adults affected by LEUKEMIA and several types of ANEMIA. Hemoglobin F,Hemoglobin, Fetal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006918 Hydroxyurea An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. Hydroxycarbamid,Hydrea,Oncocarbide
D000755 Anemia, Sickle Cell A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S. Hemoglobin S Disease,HbS Disease,Sickle Cell Anemia,Sickle Cell Disease,Sickle Cell Disorders,Sickling Disorder Due to Hemoglobin S,Anemias, Sickle Cell,Cell Disease, Sickle,Cell Diseases, Sickle,Cell Disorder, Sickle,Cell Disorders, Sickle,Disease, Hemoglobin S,Hemoglobin S Diseases,Sickle Cell Anemias,Sickle Cell Diseases,Sickle Cell Disorder
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D019332 Endothelin-1 A 21-amino acid peptide produced in a variety of tissues including endothelial and vascular smooth-muscle cells, neurons and astrocytes in the central nervous system, and endometrial cells. It acts as a modulator of vasomotor tone, cell proliferation, and hormone production. (N Eng J Med 1995;333(6):356-63) Big Endothelin,Big Endothelin-1,Endothelin Type 1,Endothelin, Big,Preproendothelin,Preproendothelin-1,Proendothelin (1-38),Proendothelin-1 Precursor,Big Endothelin 1,Endothelin 1,Endothelin-1, Big,Precursor, Proendothelin-1,Preproendothelin 1,Proendothelin 1 Precursor

Related Publications

Claudine Lapouméroulie, and Malika Benkerrou, and Marie Hélène Odièvre, and Rolande Ducrocq, and Manuel Brun, and Jacques Elion
Circulating endothelin-3 levels in patients with sickle cell disease during hydroxyurea treatment.
March 2004, Haematologica,
Claudine Lapouméroulie, and Malika Benkerrou, and Marie Hélène Odièvre, and Rolande Ducrocq, and Manuel Brun, and Jacques Elion
Stroke recurrence in Nigerian children with sickle cell disease treated with hydroxyurea.
September 2013, The Nigerian postgraduate medical journal,
Claudine Lapouméroulie, and Malika Benkerrou, and Marie Hélène Odièvre, and Rolande Ducrocq, and Manuel Brun, and Jacques Elion
Lung function decline in children with sickle cell disease treated with hydroxyurea.
January 2024, American journal of hematology,
Claudine Lapouméroulie, and Malika Benkerrou, and Marie Hélène Odièvre, and Rolande Ducrocq, and Manuel Brun, and Jacques Elion
Hydroxyurea for children with sickle cell disease.
April 2008, Pediatric clinics of North America,
Claudine Lapouméroulie, and Malika Benkerrou, and Marie Hélène Odièvre, and Rolande Ducrocq, and Manuel Brun, and Jacques Elion
Hydroxyurea for children with sickle cell disease.
February 2010, Hematology/oncology clinics of North America,
Claudine Lapouméroulie, and Malika Benkerrou, and Marie Hélène Odièvre, and Rolande Ducrocq, and Manuel Brun, and Jacques Elion
Malignancies in sickle cell disease patients treated with hydroxyurea.
October 2003, British journal of haematology,
Claudine Lapouméroulie, and Malika Benkerrou, and Marie Hélène Odièvre, and Rolande Ducrocq, and Manuel Brun, and Jacques Elion
[Homozygous Sickle Cell Children Treated with Hydroxyurea in Brazzaville (Congo)].
January 2019, Bulletin de la Societe de pathologie exotique (1990),
Claudine Lapouméroulie, and Malika Benkerrou, and Marie Hélène Odièvre, and Rolande Ducrocq, and Manuel Brun, and Jacques Elion
Is hydroxyurea leukemogenic in children with sickle cell disease?
November 2001, Blood,
Claudine Lapouméroulie, and Malika Benkerrou, and Marie Hélène Odièvre, and Rolande Ducrocq, and Manuel Brun, and Jacques Elion
Hodgkin's disease in a child with sickle cell disease treated with hydroxyurea.
September 2001, Pediatric hematology and oncology,
Claudine Lapouméroulie, and Malika Benkerrou, and Marie Hélène Odièvre, and Rolande Ducrocq, and Manuel Brun, and Jacques Elion
Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis.
October 1998, Blood,
Copied contents to your clipboard!